DURHAM, NC, GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, announced the initial closing of an $8.0 million Series C financing.
GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, announced the initial closing of an $8.0 million Series C financing. The funding round was led by Hatteras Venture Partners, with current participation from existing investors IAG Capital Partners, Alexandria Venture Investments, and Labcorp. The financing is expected to provide a cash runway for GeneCentric through 2026.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
